Jury orders J & J to pay $4.7 billion in Missouri asbestos cancer case

A Missouri jury on Thursday ordered Johnson&Johnson to pay a record $4.69 billion to 22 women who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth. In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option. “At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusion: Therefore, efforts to reduce future OBDs of ARDs, including early detection and proper management of ARDs, are needed in Korea. PMID: 30140191 [PubMed - in process]
Source: Journal of Korean Medical Science - Category: Biomedical Science Tags: J Korean Med Sci Source Type: research
A Missouri trial court judge has affirmed the massive $4.69 billion verdict against Johnson&Johnson in a case involving 22 women and their families who alleged the company's talc-based products, including its baby powder, contain asbestos and caused them to develop ovarian cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
This study strengthens the suspicion that, next to germline BAP1 alterations, other genetic factors might predispose families to the development of MM,” the authors wrote. Mutations in only one gene called BAP1 have been shown to increase risk of mesothelioma. However, experts suspect other genes may play a role in the disease. This new study supports the idea that other genes can predispose a person — or even an entire family — to mesothelioma. Hints of Genetic Influence on Mesothelioma Risk Asbestos exposure is the No. 1 cause of mesothelioma. However, some families seem to have more cases of mesothe...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Peritoneal Mesothelioma;   Fallopian Tube Adenocarcinoma;   Adenocarcinoma of the Ovary;   Primary Peritoneal Carcinoma Intervention:   Biological: MCY-M11 Sponsors:   MaxCyte, Inc.;   CTI Clinical Trial and Consulting Services Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Wall Street is trying to figure out whether the U.S. insurance industry will bear any costs from a record $4.69 billion judgment against Johnson&Johnson awarded to customers and their families who claimed that asbestos-contaminated talc caused ovarian cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Studies conducted in people have mixed results, with some indication of increased risk of ovarian cancer
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Nursing, Oncology, Pathology, Pharmacy, Institutional, Source Type: news
Results of a phase I clinical trial highlight how the addition of a drug to an existing treatment option appears safe and may improve outcomes in certain patients with malignant pleural mesothelioma (MPM). The primary goal of the trial was to determine the maximum tolerated dose of gemcitabine added to cisplatin when these drugs are delivered together as heated intraoperative chemotherapy (HIOC) during surgery. Researchers have studied cisplatin alone for HIOC. The addition of gemcitabine — a chemotherapy drug often used to treat pancreatic, ovarian and breast cancers — is new. The Journal of Thoracic Oncology...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Johnson&Johnson was ordered to pay $4.7 billion to 22 women and their families who say the company's talcum powder contributed to their ovarian cancer. The New Brunswick, New Jersey-based company (NYS: JNJ) has faced charges that its talc-based products contain asbestos. The trial was brought forward by women who contend that J&J-branded baby powder contained the cancer-causing substance dating back at least to the 1970s. They also contend that J&J knew its talc was contaminated but failed to …
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
A Missouri jury on Thursday found Johnson&Johnson liable in a lawsuit filed by 22 women who alleged the company's talc-based products, including J&J Baby Powder, contain asbestos and caused them ovarian cancer, and ordered the company to pay $550 million in compensatory damages.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news
More News: Asbestosis | Babies | Cancer | Cancer & Oncology | Health | Ovarian Cancer | Ovaries | Women